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Available online 10 January 2014Ocimum gratissimum L. is popularly used to treat diabetes mellitus. The hypoglycemic activity
of this medicinal species has been confirmed by in vivo studies. The present study conducted a
chemical investigation of a leaf decoction (10% p/v) of O. gratissimum monitored by in vivo
hypoglycemic activity assays. Four phenolic substances were identified: L-caftaric acid (1),
L-chicoric acid (2), eugenyl-β-D-glucopyranoside (3) and vicenin-2 (4). The acute hypoglyce-
mic activity of the O. gratissimum decoction fractions Og1-S (300 mg/kg), Og1-A (240 mg/kg)
and Og1-B (80 mg/kg) was evaluated intraperitoneally in normal and streptozotocin-induced
diabetic mice. They reduced glycemia by 63%, 76% and 60% (in 120 min), respectively, in the
diabetic mice. Subfractions of Og1-A were also evaluated under the same conditions: Og1-AS
(200 mg/kg) and Og1-AP (40 mg/kg) produced a decrease of only 37% and 39%, respectively.
Among the major phenolic substances, only chicoric acid (2; 3 mg/kg) reduced significantly
the glycemic levels of diabetic mice by 53%, 120 min after treatment. This is the first study
describing the hypoglycemic activity of chicoric acid in an animal model of diabetes mellitus.
In addition, we suggest that there may be other substances contributing to this activity. Thus,
for the first time, a correlation is established between the hypoglycemic activity of O. gratissimum
and its chemical composition.
© 2014 Elsevier B.V. All rights reserved.Keywords:
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Diabetes mellitus (DM) is a group of metabolic diseases,
which have hyperglycemia as a common characteristic, re-
sulting from a defect in insulin production, insulin action or
both [1,2]. Chronic hyperglycemia leads to microvascular and
macrovascular complications, the major cause of premature
mortality and morbidity among diabetic people [1,3].
DM represents a global health challenge due to its in-
creasing prevalence [4]. It affected 366 million people in 2011
and this number is likely to reach 552 million by 2030 [5].pn.ufrj.br (S.S. Costa).
All rights reserved.WHOpredicts that in 20 years, the disease will become the 7th
leading cause of death [6].
DM therapeutic options focus on glycemic control, which
encompasses appropriate diet, regular exercise, and, especially,
exogenous insulin administration and/or oral hypoglycemic
agents [7,8]. Some issues, however, limit the effectiveness of
those options, such as: failure to hinder diabetic complications
and prominent side effects [9,10]. Therefore, the search for new
therapeutic approaches to treat DM is the goal of multiple
efforts globally.
For centuries, natural products have been used to treat
diseases. They are extensively recognized as a relevant source
of drugs. As reported by Newman & Cragg (2012) of the 1355
new drugs approved between 1981 and 2010, 26% were
derived from natural products [11]. Additionally, 13% of them
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product.
The potential of medicinal plants and their bioactive
compounds to treat DM has been extensively explored, as
exemplified by the large number of reviews on this subject
[10,12–15].
The genus Ocimum (Lamiaceae) comprises 65 aromatic
species, distributed in tropical and subtropical regions world-
wide [16,17]. Species belonging to this genus are popularly used
in Africa and Asia for treating diabetic symptoms [14,18–20].
Some of them have had their hypoglycemic activity confirmed
by in vivo studies: Ocimum sanctum, Ocimum canum and
Ocimum gratissimum [18,21–25].
O. gratissimum L. is an arbustive species native from Africa,
where it is reputed for its anti-diabetic effect [19,20]. In vivo
pharmacological studies evidenced the hypoglycemic activity
of the methanol and aqueous leaf extracts from this medicinal
plant [23–25]. However the substances responsible for this
activity remain to be identified.
The present study aims to contribute to the chemical
knowledge of O. gratissimum and to identify compounds
potentially useful in the therapy of DM.
2. Materials and methods
2.1. General experimental procedures
1H and 13C NMR spectra were recorded on a Varian
VNMRS-500 (1H: 499.77 MHz; 13C: 125.68 MHz) (LAMAR -
Núcleo de Pesquisa de Produtos Naturais, UFRJ). ESI mass
spectra were obtained on a Waters Micro Q-TOF quadrupole
time of flight mass spectrometer (Instituto de Química,
UFRJ) or on a BRUKERMicroTOF-II mass spectrometer (Núcleo
de Pesquisa de Produtos Naturais, UFRJ). Specific optical
rotation ([α]D20) measurements were obtained at a P-2000
Jasco polarimeter (Núcleo de Pesquisa de Produtos Naturais,
UFRJ). HPLC-DAD analyses were performed on a Shimadzu
liquid chromatograph LC-20AT with a diode-array wavelength
SPD-M20A detector (Laboratório de Produtos Naturais, UFRJ -
Campus Macaé), using a Merck reverse-phase column C-18
(5 μm, 250 mm, 2.5 mm). Themobile phase consisted of water
containing 0.1% formic acid (eluent A) and acetonitrile con-
taining 0.1% formic acid (eluent B). The samples were run
for 50 min at 1 ml/min and the absorbance was monitored
between 200 and 500 nm. The gradient used was: 0–10 min
(100–80% A), 10–20 min (80–78% A), 20–30 min (78–75% A),
30–35 min (75–70% A), 35–40 min (70–50% A), 40–45 min
(50–30% A) and 45–50 min (30–0% A). Reversed-phase
chromatography was performed on RP-2 (70–230 mesh,
Merck) or RP-18 (40–60 μM, Merck) silanized silica (using a
water/methanol gradient) and size-exclusion chromatography
on Sephadex LH-20 gel (25–100 nm, Sigma), Sephadex G-15
(40–120 μm, Sigma) or Sephadex G-10 (40–120 μm, Sigma).
Eluates were monitored by TLC on silica 60 F254 (Merck) using
n-butanol/acetic acid/water (BAW 8:1:1 and BAW 3:1:1),
visualized under UV and revealed with cerium sulfate solution.
2.2. Plant material
O. gratissimum leaves were collected from specimens
cultivated in Barra do Piraí, RJ (Brazil), in July 2010 and July2011. The botanical species was identified by Prof. Dr. Rosana
Conrado Lopes (UFRJ, Brazil), and a voucher specimen (RFA
35593) was deposited at the herbarium of the Institute of
Biology (UFRJ, Brazil).
2.3. Extraction and isolation
Two batches of plant material submitted to extraction
were collected in 2010 (Og1) and 2011 (Og2). Extraction and
isolation procedures for these batches are described in the
following sections.
2.3.1. 1st plant batch (Og1)
The Og1 leaves were triturated in a food processor before
boiling with distilled water (10% w/v) for 5 min. The extract
obtained by decoction was filtered and concentrated at 50 °C to
approximately 1/2 of the initial volume. An aliquot correspond-
ing to 20% (2.00 g) was separated and lyophilized for analytical
and pharmacological assays. The addition of the remaining
extract to ethanol (1:1) yielded a precipitate that was separated
by filtration and subsequently lyophilized (2.02 g). The super-
natant (Og1-S) was concentrated in a water-bath until complete
evaporation of the ethanol. After the separation of a 20% (1.46 g)
aliquot, Og1-S was partitioned with n-butanol affording an
aqueous fraction (Og1-A) and a butanol fraction (Og1-B). The
yield of each fraction was calculated after lyophilization (Og1-A,
4.70 g and Og1-B, 1.13 g). Og1-A was re-suspended in distilled
water and precipitated with ethanol (1:1). The precipitate
(Og1-AP) was separated by centrifugation and lyophilized
(0.4 g). The supernatant (Og1-AS), after ethanol evaporation,
was dissolved in distilled water and lyophilized. A 52% aliquot
(1.3 mg) was separated and the remaining material (1.2 g)
was injected into a Sephadex G-15 column (30.0 × 1.1 cm,
water), giving four fractions: Og1-A-a (860 mg), Og1-A-b
(131 mg), Og1-A-c (30 mg) and Og1-A-d (13 mg).
Og1-A-b was chromatographed on a Sephadex G-10
column (12 × 1.2 cm, water) and afforded three fractions:
Og1-A-b1 (87 mg), Og1-A-b2 (30 mg) and Og1-A-b3 (7 mg).
The fraction Og1-A-b1 was purified on a Sephadex LH-20
column (32 × 0.8 cm, water/methanol 50%), yielding com-
pound 1, a phenolic acid (13 mg).
Fraction Og1-A-c was chromatographed on a Sephadex
LH-20 column (19 × 0.7 cm, water/methanol 50%), affording
two fractions: Og1-A-c1 (10 mg) and Og1-A-c2 (15 mg). The
last one, Og1-A-c2,was purified on a Sephadex LH-20 column
(32 × 0.8 cm, water/methanol 50%) and gave compound 2, a
second phenolic acid (6 mg).
Fraction Og1-A-d was purified on a Sephadex LH-20
column (32 × 0.8 cm, water/methanol 50%), affording 3 mg
of a flavonoid rich fraction: Og1-A-d2.
Og1-B (560 mg)was re-suspended in distilledwater (12 ml)
and centrifuged (3000 rpm, 10 min). The insolublematerial was
lyophilized (109 mg). The supernatant was partitioned with
ethyl acetate, affording an aqueous fraction (Og1-BAq, 383 mg)
and an acetate fraction (Og1-BAc, 67 mg). The yield of each
fraction was calculated after evaporation of the organic solvent
and lyophilization.
An aliquot of Og1-BAq (330 mg) after chromatography
on an RP-2 column (25 × 1.1 cm, water/methanol gradient)
gave four fractions: Og1-BAq-1 (water, 93 mg), Og1-BAq-2
(water, 87 mg), Og1-BAq-3 (methanol 10%, 23 mg) and Og1-
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Og1-BAq-3 originated 4 mg of a flavonoid-containing precip-
itate (Og1-BAq-3P), separated by centrifugation (3000 rpm,
10 min). The supernatant of this fraction was injected in a
Sephadex G-10 column (20 × 0.4 cm, water), giving the flavo-
noid fraction Og1-BAq-3b (4.5 mg).
2.3.2. 2nd plant batch (Og2)
Leaves from batch Og2 were extracted and fractioned by
similar procedures used for Og1. A 10% (w/v) decoction
was prepared from triturated fresh leaves. The extract was
concentrated to 1/2 of the initial volume. An aliquot of 45%
(6.07 g) was separated and lyophilized, while the remaining
extract was precipitated with ethanol (1:1), yielding 1.06 g
of precipitate. The supernatant (Og2-S) was partitioned with
n-butanol giving an aqueous fraction (Og2-A, 3.70 g) and a
butanol fraction (Og2-B, 0.80 g).
An aliquot of Og2-B (480 mg)was re-suspended in distilled
water (10 ml) and centrifuged (3000 rpm, 10 min), affording
an insolublematerial (129 mg). The supernatantwas extracted
with ethyl acetate, giving an aqueous fraction (Og2-BAq,
180 mg) and an acetate fraction (Og2-BAc, 99 mg).
Og2-BAc was injected on a Sephadex LH-20 column
(25.5 × 1.3 cm, ethanol), yielding 2 fractions: Og2-BAc-1
(47 mg) and Og2-BAc-2 (9 mg). Og2-BAc-1 was chromato-
graphed on the same column and afforded two fractions:
Og2-BAc-1a (30 mg) and Og2-BAc-1b (10 mg). Og2-BAc-1a
was purified on an RP-18 column (19 × 1.3 cm, water/
methanol gradient), giving 5 mg of the phenolic compound 3.
Og2-BAq was chromatographed on an RP-2 column
(25 × 1.1 cm, water/methanol gradient), yielding five fractions:
Og2-BAq-1 (water, 42 mg), Og2-BAq-2 (water, 22 mg), Og2-
BAq-3 (methanol 10%, 38 mg), Og2-BAq-4 (methanol 10–50%,
7 mg) and Og2-BAq-5 (methanol 50–100%, 8 mg). Og2-BAq-3
was purified on a Sephadex G-10 column (12 × 1.2 cm, water)
and afforded a flavonoid-enriched fraction: Og2-BAq-3b (8 mg).
The chromatography of Og2-BAq-4 on an RP-18 column
(21 × 0.8 cm, water/methanol gradient) originated an addition-
al amount of compound 3 (3 mg).
The flavonoid-rich fractions Og1-BAq-3P, Og1-BAq-3b,
Og1-A-d2 and Og2-BAq-3b obtained from Og1 and Og2
were grouped and injected into a Sephadex LH-20 column
(32 × 0.8 cm, water/methanol 50%). From this fractionation
the flavonoid compound 4 (9 mg) was obtained.
2.4. 1H NMR analysis of fractions from O. gratissimum
The chemical profiles of three fractions from the decoction
of O. gratissimum were compared by 1H NMR (Og1-A, Og1-AS
and Og1-AP). A 5 mg sample of each fraction was dissolved in
0.75 ml of D2O with 0.05% of 3-(trimethylsilyl)propionic-
2,2,3,3-d4 acid sodium salt (TSP-d4). 1H NMR spectra were
acquired at 25 °C with 256 scans, 0.24 Hz/point, spectral width
(SW) = 8012.8 Hz, relaxation delay (RD) = 1.0 s, and receiver
gain (RG) = 30. TSP-d4 signal was used as a reference for
integration of signals and comparison of different spectra.
2.5. Diabetes induction and treatment
Male Swiss mice (8 weeks old) were housed in a
temperature-controlled room, with a 12-hour light–darkcycle, having free access to water and food. DMwas induced
through a single intraperitoneal (i.p.) dose (150 mg/kg) of
streptozotocin (STZ) dissolved in sodium citrate (100 mM,
pH 4.5) as described by Da Silva et al. (2010) [26]. Control
group received only sodium citrate i.p. After 5 days, the mice
that had developed hyperglycemia (≥300 mg/dl) were
considered diabetic. Diabetic mice, as well as normal ones,
were divided into control groups (n = 9) and treatment
groups (n = 3). Normal and diabetic mice were treated with
i.p. injection of human regular insulin (Humulin — 2 U/kg),
Og1-S (300 mg/kg), Og1-B (80 mg/kg), Og1-A (240 mg/kg),
Og1-AS (200 mg/kg), Og1-AP (40 mg/kg), compounds 1 and
2 (3 mg/kg) and compound 4 (4 mg/kg). Doses of the
fractions and substances were chosen according to their
approximate yield. All samples were lyophilized and stored
under low temperature (−20 °C) in order to avoid degrada-
tion of possible active components. Fractions and phenolic
substances were diluted in saline solution (NaCl 0.9%) for
100 μl of injection. Normal and diabetic control groups
received only saline solution. Fasting glucose levels were
measured from blood mice samples drawn by tail snip before
(t = 0) and 1 and 2 h after the treatment using a glucometer
(Accu-Chek_ Active— Roche). This protocol (Ref. Nr. NPPN01)
was approved by the internal institutional animal use commit-
tee (CEUA — CCS/UFRJ).
2.6. Statistical analysis of data
Results were expressed as means ± SEM. Differences be-
tween two values were determined using Student's t-test and
data were considered different at a significance level of P b 0.05.
Analyses were performed using the Sigma Plot 11.0 software.
3. Results and discussion
3.1. Phytochemical study
The phytochemical study of theO. gratissimum aqueous leaf
extract led to isolation of four phenolic compounds: L-caftaric
acid (1), L-chicoric acid (2), eugenyl-β-D-glucopyranoside (3)
and vicenin-2 (4). Phenolic acids 1 and 2 were obtained from
the aqueous fraction (Og1-A), while phenylpropanoid 3 was
isolated from the butanol fraction (Og2-B) and flavonoid 4
from the aqueous and butanol fractions (Og1-A, Og1-B, Og2-B).
These substances are shown in Fig. 1, and have already been
isolated from other vegetal sources. Their structures are in
accordance with UV, MS and NMR data reported early by
Mulkens & Kapetanidis (1988), Xie et al. (2003), Sobolev et al.
(2005),Maier et al. (2006), Nuissier et al. (2010) and Zeng et al.
(2011) [27–32]. The fractionation process used in this study is
summarized in Fig. 2.
Compounds 1 and 2 are esters of caffeic and tartaric acids,
respectively. Specific optical rotation ([α]D20) value measured
for caftaric acid was−14.5° (c = 0.7, H2O), while for chicoric
acid was−263.9° (c = 0.5, H2O). These values seem compat-
ible with L-caftaric and L-chicoric acids. Lamidey et al. (2002)
reported a specific rotation of −242.7° ([α]D22, c = 0.89,
methanol) for L-chicoric acid, a value similar to that observed
in our study [33]. Scarpati and Oriente (1958) however found a
quite different value: −384.2° ([α]D25, c = 1.075, methanol)
using the same solvent employed by Lamidey et al. (2002) [34].
Fig. 1. Structures of isolated compounds: L-caftaric acid (1), L-chicoric acid (2), eugenyl-β-D-glucopyranoside (3) and vicenin-2 (4).
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[35]. It is important to note that temperature, solvent and/or
concentration used in the literature are different from those
used in our study, which may influence the results [36].
Ola et al. (2009) detected vicenin-2 and chicoric acid in
O. gratissimum leaf decoction by HPLC-DAD-MS analysis [37].
However, those substances were not isolated. Chicoric acid
is typically found in the family Asteraceae, although it is also
reported in some species from other families, such as
Lamiaceae in which the genus Ocimum is included [38]. It
is important to point out that this is the first report on
caftaric acid and eugenyl-β-D-glucopyranoside in O.
gratissimum. The former seems to be a way to store eugenol,
the major constituent of the essential oil of O. gratissimum
cultivated in Brazil [39,40]. Phenylpropane glycosides thatFig. 2. Flowchart of Og fractionation. Numbers represent compounds 1–4. Frfrequently occur in plants are cleaved to their correspond-
ing aglycones by enzymatic processes and thus increase the
quantity of essential oil in the plant [41].
3.2. Hypoglycemic activity assay of supernatant, aqueous and
butanol fractions
The decoction fractionation of the leaves from O. gratissimum
collected in 2010 (Og1) was monitored by acute hypoglycemic
activity assays in streptozotocin-induced diabetic mice.
The decoction was precipitated with ethanol in order to
promote an initial fractionation, and afforded a precipitate and
a supernatant (Og1-S). This procedure allows the separation of
the polysaccharides, proteins and salts as insoluble materials,
while the micro-metabolites remain in the supernatant [42].actions and compounds highlighted were pharmacologically assayed.
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butanol fraction (Og1-B) and an aqueous fraction (Og1-A).
Initially the hypoglycemic activity of Og1-S and its fractions,
Og1-A and Og1-B was evaluated. The results are shown in
Fig. 3. Insulin treatment promptly decreased glycemia of either
normal or diabetic mice showing that they were responsive to
this hormone.
Og1-S and both fractions Og1-A and Og1-B produced
significant glycemia reduction in diabetic mice, by 63%, 76%
and 60%, respectively. The major fraction Og1-A was the most
active. After 120 min, the glycemic levels of diabetic treated
mice were not statistically different from normal untreated
mice. On the other hand, all three samples produced no great
effect on normal mice. The decreased blood glucose concen-
tration observed in normal groups and untreated diabetic
groups over time of treatment appears to be related to fasting.
The hypoglycemic activity of O. gratissimum leaf extracts has
already been reported in other studies. Aguiyi et al. (2000)
evaluated the effect of a methanolic extract in alloxan-induced
diabetic rats. In this study the extract, which was intraperito-
neally injected at a dose of 400 mg/kg, lowered the glycemic
levels of normal and diabetic mice 180 min after treatment
by 56% and 68%, respectively [23]. However, it is important to
emphasize that the qualitative and quantitative chemical
compositions of a plant extract obtained with methanol may
be considerably different from that obtainedwithwater [43,44].
In the above mentioned study, the authors only suggested the
presence of saponins and tannins in the methanolic extract.
Egesie et al. (2006) evaluated the toxicity and the in vivo
chronic hypoglycemic activity of a decoction fromO. gratissimum
leaves [24]. The extract orally administered at doses of 500–
1500 mg/kg was not toxic and produced a reduction in the
glycemic levels of streptozotocin-induced diabetic rats after 14
and 28 days. The chemical composition of the extract was not
reported by the authors.
In a recent study, an aqueous O. gratissimum leaf extract
exhibited hypoglycemic activity on type-2 diabetic rats. The
extract administered orally at a dose of 200 mg/kg was able
to reduce significantly the post-prandial glycemic levels of
diabetic rats in comparison with the control rats, after 30, 60,Con Con-I Con-S Con-B Con-A
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3.3. Hypoglycemic activity assays of subfractions from the aqueous
fraction (Og1-A)
Due to higher hypoglycemic activity and greater mass
availability, Og1-A was selected for further fractionation. This
fraction was precipitated with ethanol. The hypoglycemic ac-
tivities of the two subfractions obtained, Og1-AS and Og1-AP,
were subsequently evaluated. The results are shown in Fig. 4.
Og1-A exhibited a very high activity while both subfractions
Og1-AS and Og1-AP tested in doses proportional to their yield
had low activity on diabetic mice. The reduction rates observed
for these fractions were 37% and 39%, respectively. These results
indicate that fractionationwas detrimental for the hypoglycemic
activity.
In order to explain these findings two hypothesis were
formulated: the substances present in both subfractions are
important for the activity or the fractionation procedure
produced degradation of the active substances. To investigate
the second hypothesis, we tested a pool of the two subfractions
in the proportion in which each is represented in the mother
fraction (1:5). The results obtained are also shown in Fig. 4. The
pool of fractions had higher activity on diabetic mice reducing
their glucose levels by 61%. The glycemia of treated mice was
not statistically different from normal mice after 120 min, as
observed for Og1-A. This result suggests that the fractionation
did not modify the chemical structure of bioactive substances
since the activity of the pool of both subfractions was not
significantly different from that observed for themother fraction.
Thus the first hypothesis seems to be the most plausible.
In order to investigate the composition of the aqueous
fraction and its two subfractions, they were analyzed by HPLC-
DAD and by 1H NMR (Fig. 5). The major fraction Og1-AS has a
composition very similar to that of Og1-A as can be seen in the
1H NMR spectra (Fig. 5). The fraction and subfractions also
presented similar phenolic compositions, exhibiting chicoric
and caftaric acids as their major substances. The minor sub-
fraction Og1-AP has a much lower phenolic concentration. TheSTZ STZ-I STZ-S STZ-B STZ-A
0
100
200
300
400
500
600
700
0
60
120
Time (min):
*
*
#*
#*
#*
#* #*
*
#*
#*
B
eated with saline (n = 9); Con-I: normal mice treated with insulin (2 U/kg;
al mice treated with Og1-B (80 mg/kg; n = 3); Con-A: normal mice treated
); STZ-I: diabetic mice treated with insulin (2 U/kg; n = 3); STZ-S: diabetic
-B (80 mg/kg; n = 3); STZ-A: diabetic mice treated with Og1-A (240 mg/kg;
-test). #P b 0.05 compared with control mice (Student's t-test).
Con Con-I Con-AP Con-AS Con-AP+AS
G
lyc
em
ia
 (m
g/d
l)
0
100
200
300
400
500
600
700
0
60
120
*
#*
#*
Time (min):
STZ STZ-I STZ-AP STZ-AS STZ-AP+AS
0
100
200
300
400
500
600
700
0
60
120
Time (min):
*
*
#*
#*
#*
#* #*
*
#*
#*
BA
Fig. 4. Hypoglycemic activity of Og1-AP, Og1-AS and the pool of both subfractions. (A) Con: normal mice treated with saline (n = 9); Con-I: normal mice treated
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two subfractions. A singlet signal at 4.37 ppm compatible with
the presence of tartaric acid was clearly intensified in the
Og1-AP sample. This signal was three times greater in Og1-AP
than in Og1-AS. We assume that this substance contributes to
the hypoglycemic activity, since this activity decreases when it
is separated from themixture. Therewas also a pair of doublets
(2.54 ppm; J = 16.5 Hz and 2.71 ppm; J = 16.6 Hz) sharper
and more intense in Og1-AP, which seems to be compatible
with citric acid. These signals are 35% greater in this fraction
when compared to Og1-AS.
Tartaric acid is used as an excipient in many pharmaceutical
formulations and shows no significant pharmacological activi-
ties. However, in spite of that, the use of tartaric acid as an
excipient can increase the intestinal absorption of substances
through some putative mechanisms: intermolecular interac-
tions, glycoprotein P inhibition and enhancement of paracellular
transport [45–47]. Some of these mechanisms possibly contrib-
ute in some extent to absorption through the peritoneal barrier,
considering that intraperitoneally administered substancesmust
transpose it to gain the bloodstream [48].3.4. Hypoglycemic activity assays of compounds 1, 2 and 4
We also evaluated the two phenolic acids isolated from
Og1-A, compounds 1 and 2 (3 mg/kg), in order to investigate
their eventual role in the hypoglycemic activity observed for the
fractions. Of both substances tested, only compound 2 (chicoric
acid) exhibited significant hypoglycemic activity on diabetic
mice (60 and 120 min after treatment). The reduction rate was
54%, as shown in Fig. 6. This result suggests that compound
2 contributes to the hypoglycemic activity observed for
O. gratissimum. However, this phenolic acid is not likely to be
the only component responsible for the hypoglycemic activity,
since the isolated substance is less active than the fraction.
The flavonoid 4, isolated from Og1-A and Og1-B, was
evaluated at a dose of 4 mg/kg but did not show any hypo-
glycemic activity under the same conditions (data not shown).
Compound 3was not tested because it was obtained only fromthe second plant batch (Og2), whose fractionation was not
biomonitored.
Chicoric acid was described by Tousch et al. (2008) [49] as
a potential anti-diabetic agent. In this in vitro study the
substance was able to increase insulin secretion from β-cells
and to enhance muscle cell sensitivity to insulin. Chlorogenic
acid, a monocaffeoyl ester of quinic acid, was also assayed
and exhibited a similar activity [49]. A putative mechanism
for the insulin-sensitizing activity of these two substances is
the inhibition of protein tyrosine phosphatase 1B (PTP1B), a
negative regulator of insulin sensitivity [50].
Chicoric and chlorogenic acids frequently co-occur in plant
species [51–53]. Nevertheless, this substance is not reported in
O. gratissimum and was not detected in the present study.
The anti-diabetic potential of chicoric acidwas also evaluated
in vivo. As described in a patent, the intraperitoneal administra-
tion of chicoric acid to normal rats at a dose of 5 mg/kg was able
to potentiate the insulin response to glycemia, increasing insulin
secretion [54]. Additionally, a chicoric acid-enriched extract (85–
95% of purity) obtained from Cichorium intybus increased glucose
tolerance on normal rats, at daily doses of 5, 15 and 30 mg/kg
(i.p.) administered for four days. The beneficial effect produced
by the extract was probably related to an insulin-sensitizing
action [55].
However, it is important to note that the studies mentioned
above were based on in vitro tests and on in vivo assays
with normal animals. Therefore, as far as we know we have
demonstrated here for the first time the hypoglycemic activity of
chicoric acid in a diabetic animalmodel.We can find in literature
many reports on in vivo hypoglycemic activity for caffeic acid
esters, such as chlorogenic acid, romarinic acid and caffeic acid
phenethyl ester [56–58]. These substances showed to be
responsible for hypoglycemic activity of several medicinal plants
[56,59,60]. Most of these studies, however, describe the effects of
long-term treatments on glycemic parameters, which hinder
comparison with the acute effects evaluated in our assays.
Nevertheless, studies on in vivo acute hypoglycemic activity
for caffeic and chlorogenic acids were reported. Chlorogenic
acid (10 mg/kg) showed significant hypoglycemic activity
when orally administered to STZ-induced diabetic rats. The
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138 L.M. Casanova et al. / Fitoterapia 93 (2014) 132–141reduction rate observed after 180 min was 26% [61]. Addition-
ally, caffeic acid intravenously administered to diabetic rats
(3 mg/kg) reduced glycemic levels in 24–33% after 30 min[62]. As caffeic acid is a product of caffeoyl ester metabolism, it
could possibly account for the hypoglycemic activity of these
substances, as suggested by Tsuda et al. (2012) [63].
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donot corroborate this hypothesis. The authors assayed in vitro
ferulic acid, caffeic acid and a chicoric acid enriched-extract and
observed different pharmacological profiles for these sub-
stances. While the chicoric acid-enriched extract stimulated
insulin release on pancreatic cells as expected, caffeic acid
produced an opposite effect, decreasing insulin secretion from
these cells. On the other hand, caffeic acid was able to reduce
glycogenolysis on hepatocytes, which was not observed for
chicoric acid-enriched extract.
Furthermore, in the present study the monocaffeoyl ester,
caftaric acid (1) revealed to be inactive under the same con-
ditions where chicoric acid was active. It is possible that both
caffeoyl moieties are required for acute hypoglycemic activity
in ourmodel. The possible influence of pharmacokinetic factors
that may favor the bioavailability of the dicaffeoyl over the
monocaffeoyl ester should also be taken into consideration.
Direct comparison with literature data on acute hypoglycemic
activity of caffeic and chlorogenic acids is difficult because the
animal model and administration route (i.p.) used in our study
were different from those used in the previous reports above
mentioned.
There is no data on chicoric acid bioavailability as far as we
know. On the other hand, the bioavailability of caffeoylquinic
acid esters (chlorogenic acids) in humans after coffee con-
sumption is reported in a number of studies, yet, it is a
controversial subject, as discussed by Erk et al. (2012) [64].
While in some studies a high bioavailability was observed (up
to 70%) [65,66], the authors above mentioned detected much
lower plasma concentrations of these substances after inges-
tion of different doses [64] due to their extensive metabolism.
Caftaric acid, in turn, is only detectable in small amounts
in plasma after wine consumption [67]. This substance is
hydrolyzed by intestinal enzymes. There are evidences that
chicoric acid is hydrolyzed as well, although it was not yetassayed in vivo [68]. In the present study compounds were not
orally administered. A new set of in vivo experiments is
necessary to investigate the effects of oral administration of
fractions and compounds from O. gratissimum on glycemic
levels in view of clarifying these issues.
4. Conclusion
In this study a correlation is established for the first time
between O. gratissimum hypoglycemic activity and its
chemical composition by means of a biomonitored fraction-
ation. Chicoric acid, the active substance identified, is not
likely to be the only compound responsible for the hypogly-
cemic activity. Results obtained suggested a possible inter-
action between chicoric acid and a substance present in the
precipitate from the aqueous fraction, probably tartaric acid.
This interaction is under investigation in our laboratories.
From the above observations, it was possible to conclude that
O. gratissimum is a promising source of hypoglycemic agents.
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